Related Experiment Videos
[Use ciprofloxacin in children with mucoviscidosis]
Insights
Ciprofloxacin effectively improved symptoms in children with cystic fibrosis (mucoviscidosis) and Pseudomonas aeruginosa lung infections. However, the antibiotic did not eradicate the bacteria, with some patients experiencing adverse effects.
Area of Science:
- Pediatric Pulmonology
- Infectious Diseases
- Pharmacology
Abstract:
Ciprofloxacin was used in treatment of 13 children aged 6 to 18 years with mucoviscidosis and exacerbation of the bronchopulmonary process. The dose of the drug was 20 to 30 mg/kg a day when administered orally or 15 mg/kg a day when administered at first intravenously and then orally. The treatment course averaged 14 days. The indications to the drug use were: severe processes of mucoviscidosis and chronic colonization of the bronchial mucosa and lung tissues with Pseudomonas aeruginosa (mucoid or nonmucoid form) sensitive to ciprofloxacin and resistant to other antibiotics. The trials showed that ciprofloxacin was highly efficient: the state of the patients improved and the inflammation index of the total blood count normalized. However, eradication of P. aeruginosa from the respiratory tracts was not observed. The drug allergy in 1 patient and a transient increase in the level of transaminases in 5 patients as the adverse reactions were recorded.